MARAbio's vision is a world in which the most severe effects of autism do not occur.

To detect Maternal Autoantibody Related Autism (MARA) and prevent the development of profound autism.

Redefining the life experience for people with intellectual and developmental disabilities.

Trucyto is developing innovative genomic medicine-based products to selectively kill cancer cells

Consult with General Partners regarding potential investment opportunities to provide initial vetting of potential investments, support due diligence, assist GPs in CEO & team assessment, and provide operational guidance to portfolio investments and mentoring of CEOs, as appropriate.

Applied Biosensors is providing cutting-edge sensor technology for process control in biomanufacturing.

Circular Genomics is a venture-backed startup company developing precision diagnostics utilizing circular RNAs as biomarkers to provide personalized care for patients with psychiatric and neurological disorders.

Bionano acquired Lineagen in August of 2020 to create an industry leader in cytogenetics through a combination of proprietary systems and consumables, commercial and clinical expertise in genetic diagnostic clinical services, and proprietary testing and interpretation technology.- Member of Senior Management Team reporting directly to Chief Executive Officer; responsible for establishing key strategic initiatives for merged Bionano-Lineagen entity.- Significant increase in acquisition value (+500% increase in share price), commercial performance (50% increase in year-over-year quarterly revenues), and capital formation (+$100M public offering to advance strategic initiatives of the merged entity) after the first full quarter of operations.

Built and led a venture capital-backed company from start-up through strategic exit, including: developing and implementing an integrated product development, marketing, sales, and managed care reimbursement strategy to commercialize the company's first offering from concept to $70+ million in revenue since launch.- Raised over $75M in venture capital and venture debt financings between 2007 and 2020.- Sourced and secured 5 separate letters of interest, led negotiations, and successfully completed an M&A transaction with Bionano Genomics, a NASDAQ-listed acquirer.- Led the implementation of a series of operational and commercial initiatives to improve path to profitability, which resulted in significant year-over-year improvements in gross profit margins (+54%), contribution margins (+108%), EBITDA (+59%), and Cash Burn (71% reduction). - Worked effectively with Board of Directors in establishing strategic and operational directives for corporation, including due diligence on multiple M&A opportunities.- Grew company to approximately 125 employees and annual top-line revenue to approximately $20M.- Completed all start-up formation and incorporation activities and negotiated broad IP license agreements with academic medical center institutional founders and partners, including The University of Utah, The Children’s Hospital of Philadelphia (the first equity-bearing license by CHOP), and Toronto Hospital for Sick Children.- Developed and implemented a strategy for the design, manufacture, and launch of customized genetic tests that incorporate validated proprietary scientific findings; resulted in peer-reviewed data that demonstrated 25% higher clinical utility vs. comparator tests. - Achieved +80% cumulative annual growth in customer orders, revenue, and cash collections first 5 years on the market.- Secured managed care contracts covering over 90 million U.S. lives.

- Participated in all aspects of venture capital investing, including deal sourcing, product/service evaluation, competitive analysis, “go/no go” recommendations on new investments and on-going investments in existing portfolio companies.- Evaluated and made recommendations on 100+ companies in the biotechnology, medical device, and diagnostics industry. Representative investments included, but not limited to: development of nebulized drugs for COPD by Elevation Pharmaceuticals (acquired in 2012 for up to $430 million by Sunovian) and development and commercialization of diagnostic tests for autoimmune diseases by Exagen Diagnostics (completed IPO in 2019 at ~$168M valuation).

- Formulated and implemented a unique sponsored research and licensing business model with state and university stakeholders that generated greater than 150 percent IRR on research project commercialization through the execution of multiple corporate partnerships with world-leading biotechnology and pharmaceutical companies, including: Amgen, Merck, IBM, Bristol-Myers and Celera Diagnostics.- Completed corporate contractual milestones that repaid $3.73M in loan obligations, more than 2 years ahead of scheduled repayment period.- Managed budget to within 1% variance on expense side and exceeded top-line budget projections by more than 50%.

- Member of core strategic team responsible for seeking Series A financing for a start-up cancer-focused biotechnology company that secured a term sheet for $50 million.- Directed all aspects of corporate business development activities, including forming cross-functional teams to identify, evaluate, and implement business opportunities. - Directed the intellectual property and licensing strategy of the Huntsman Cancer Foundation and Huntsman Biotechnology Corporation.

- Chaired and directed the activities of a product development group responsible for advancing a strategic product development plan of the Company’s programs, including recombinant versions of human glucagon-like peptide 2 (now FDA-approved as GATTEX®) and parathyroid hormone (now FDA-approved as Natpara®) which at the time was the Company’s first Phase III clinical candidate at the FDA. - Presented strategic product development recommendations and alternatives to corporate Senior Management and Board of Directors.- Analyzed new business opportunities and transactions, including M&A with corporate CEO, CSO, CFO and VP of Business Development/Operations.- Managed full spectrum of intellectual property estate responsibilities for a mid-cap biopharmaceutical company, including: analysis of company and third party technologies, management and direction of internal and external patent counsel (Amgen, Inc. and Kirin) for prosecution of international patent estate for Cinacalcet HCl (now FDA-approved as Sensipar®), and the definition and execution of business plans for extracting value from non-core corporate intellectual assets.

- Managed full spectrum of intellectual property estate responsibilities for a mid-cap biopharmaceutical company, including: analysis of company and third party technologies; management and direction of internal and external patent counsel; and the definition and execution of business plans for extracting value from non-core corporate intellectual assets.

- Managed full spectrum of intellectual property estate responsibilities for a mid-cap biopharmaceutical company, including: analysis of company and third party technologies, management and direction of internal and external patent counsel (Amgen, Inc. and Kirin) for prosecution of international patent estate for Cinacalcet HCl (now FDA-approved as Sensipar®), and the definition and execution of business plans for extracting value from non-core corporate intellectual assets.

- Self-initiated first-ever biotechnology licensing internship at UUTTO; evaluated inventions for potential commercial applications and for patentability. Maintained invention disclosure records and summaries. Created reports detailing invention status and activity; initiated market studies and formulated marketing plans for inventions and marketed inventions to industry.

- Department of Pathology, University of Utah. Advisor – John Weis, Ph.D.

- Division of Immunology and Rheumatology, Harvard Medical School. Advisor – John Weis, Ph.D.

- Embryology-Teratology Unit. Advisor – L.B. Holmes, M.D.